Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MW7S
|
|||
| Former ID |
DIB005929
|
|||
| Drug Name |
Lexatumumab
|
|||
| Synonyms |
HGS-ETR2; TRAIL receptor-2 monoclonal antibodies (cancer), HGS/CAT; TRAIL-R2 mAbs (cancer), Human Genome Sciences/Cambridge Antibody Technology; TNF-related apoptosis-inducing ligand receptor-2 mAbs (cancer), HGS/CAT
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Cambridge Antibody Technology Group plc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr Opin Mol Ther. 2006 Dec;8(6):539-46. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 528015). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.